Diagnosis of Alzheimer’s disease (AD) is currently largely based on the presence of biomarkers. This may lead to a problematic over-diagnosis if this is incorrectly interpreted. To counter this problem, a global expert panel led by Hôpitaux universitaires de Genève (HUG), the University of Geneva and the Salpêtrière Hospital have drawn up recommendations.